Skyrizi 150 mg injection available for plaque psoriasis

Skyrizi is now available as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis in the United States, AbbVie announced in a press release.

The Skyrizi (risankizumab-rzaa) 150 mg pen, an interleukin-23 inhibitor that is administered with one injection per dose every 12 weeks after two starter doses, was approved by the FDA in April.

The injection can replace two 75 mg injections.

“We know many people living with psoriasis are looking for flexibility in how they manage their disease,” Patrick Horber, president of U.S. Immunology at AbbVie, said in the release. “That’s why we’re proud to provide an updated Skyrizi treatment experience that allows for fewer injections of the same Skyrizi that patients and providers have come to know and trust.”